Daniel Klamer

973 total citations
34 papers, 790 citations indexed

About

Daniel Klamer is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Social Psychology. According to data from OpenAlex, Daniel Klamer has authored 34 papers receiving a total of 790 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Cellular and Molecular Neuroscience, 20 papers in Molecular Biology and 11 papers in Social Psychology. Recurrent topics in Daniel Klamer's work include Neuroscience and Neuropharmacology Research (16 papers), Receptor Mechanisms and Signaling (16 papers) and Neurotransmitter Receptor Influence on Behavior (12 papers). Daniel Klamer is often cited by papers focused on Neuroscience and Neuropharmacology Research (16 papers), Receptor Mechanisms and Signaling (16 papers) and Neurotransmitter Receptor Influence on Behavior (12 papers). Daniel Klamer collaborates with scholars based in Sweden, Ireland and United States. Daniel Klamer's co-authors include Lennart Svensson, Jörgen A. Engel, Erik Pålsson, Caroline Wass, Kim Fejgin, Trevor Archer, John Lowry, Nicholas Waters, Walter E. Kaufmann and Jeffrey Sprouse and has published in prestigious journals such as Scientific Reports, Neuropsychopharmacology and Psychopharmacology.

In The Last Decade

Daniel Klamer

33 papers receiving 757 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Klamer Sweden 20 435 320 150 139 133 34 790
T.I.F.H. Cremers Netherlands 13 455 1.0× 250 0.8× 150 1.0× 99 0.7× 98 0.7× 20 846
Amy Bullock United States 16 420 1.0× 513 1.6× 124 0.8× 83 0.6× 81 0.6× 22 949
Michael M. Poe United States 18 511 1.2× 418 1.3× 84 0.6× 145 1.0× 147 1.1× 42 961
Inna Gaisler‐Salomon Israel 18 341 0.8× 373 1.2× 152 1.0× 73 0.5× 137 1.0× 33 898
Michel M. M. Verheij Netherlands 18 555 1.3× 338 1.1× 132 0.9× 93 0.7× 63 0.5× 48 922
Katherine M. Nautiyal United States 16 302 0.7× 231 0.7× 89 0.6× 87 0.6× 99 0.7× 26 777
Brice Le François Canada 14 284 0.7× 272 0.8× 84 0.6× 63 0.5× 99 0.7× 17 663
Yoko Hagino Japan 16 537 1.2× 309 1.0× 59 0.4× 62 0.4× 79 0.6× 46 779
Jesse W. Richardson-Jones United States 7 472 1.1× 286 0.9× 141 0.9× 53 0.4× 116 0.9× 7 759
James R. Shoblock United States 16 539 1.2× 394 1.2× 82 0.5× 122 0.9× 88 0.7× 23 1.1k

Countries citing papers authored by Daniel Klamer

Since Specialization
Citations

This map shows the geographic impact of Daniel Klamer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Klamer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Klamer more than expected).

Fields of papers citing papers by Daniel Klamer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Klamer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Klamer. The network helps show where Daniel Klamer may publish in the future.

Co-authorship network of co-authors of Daniel Klamer

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Klamer. A scholar is included among the top collaborators of Daniel Klamer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Klamer. Daniel Klamer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kaufmann, Walter E., et al.. (2019). ANAVEX®2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome. Pharmacology Biochemistry and Behavior. 187. 172796–172796. 37 indexed citations
2.
Waters, Nicholas, et al.. (2018). Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington’s Disease. Journal of Huntington s Disease. 7(1). 1–16. 20 indexed citations
3.
Klamer, Daniel, et al.. (2015). Increased brain nitric oxide levels following ethanol administration. Nitric Oxide. 47. 52–57. 24 indexed citations
4.
Waters, Nicholas, et al.. (2014). The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression. Journal of Neural Transmission. 121(11). 1337–1347. 12 indexed citations
5.
Wass, Caroline, Daniel Klamer, Erik Pålsson, et al.. (2011). L-lysine as adjunctive treatment in patients with schizophrenia: a single-blinded, randomized, cross-over pilot study. BMC Medicine. 9(1). 40–40. 18 indexed citations
6.
Klamer, Daniel, Lennart Svensson, Kim Fejgin, & Erik Pålsson. (2010). Prefrontal NMDA receptor antagonism reduces impairments in pre-attentive information processing. European Neuropsychopharmacology. 21(3). 248–253. 7 indexed citations
7.
Pålsson, Erik, John Lowry, & Daniel Klamer. (2010). Information processing deficits and nitric oxide signalling in the phencyclidine model of schizophrenia. Psychopharmacology. 212(4). 643–651. 9 indexed citations
8.
Pålsson, Erik, Göran Söderlund, Daniel Klamer, & Filip Bergquist. (2010). Noise benefit in prepulse inhibition of the acoustic startle reflex. Psychopharmacology. 214(3). 675–685. 14 indexed citations
9.
Fejgin, Kim, et al.. (2009). Prefrontal GABAB Receptor Activation Attenuates Phencyclidine-Induced Impairments of Prepulse Inhibition: Involvement of Nitric Oxide. Neuropsychopharmacology. 34(7). 1673–1684. 28 indexed citations
10.
Wass, Caroline, Daniel Klamer, Kim Fejgin, & Erik Pålsson. (2009). The importance of nitric oxide in social dysfunction. Behavioural Brain Research. 200(1). 113–116. 19 indexed citations
11.
Wass, Caroline, Lennart Svensson, Kim Fejgin, et al.. (2008). Nitric oxide synthase inhibition attenuates phencyclidine-induced disruption of cognitive flexibility. Pharmacology Biochemistry and Behavior. 89(3). 352–359. 19 indexed citations
12.
Pålsson, Erik, Kim Fejgin, Caroline Wass, & Daniel Klamer. (2008). Agmatine attenuates the disruptive effects of phencyclidine on prepulse inhibition. European Journal of Pharmacology. 590(1-3). 212–216. 27 indexed citations
13.
Fejgin, Kim, Erik Pålsson, Caroline Wass, et al.. (2007). The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology. 191(2). 377–385. 28 indexed citations
14.
Wass, Caroline, Trevor Archer, Erik Pålsson, et al.. (2006). Effects of phencyclidine on spatial learning and memory: Nitric oxide-dependent mechanisms. Behavioural Brain Research. 171(1). 147–153. 43 indexed citations
15.
Klamer, Daniel, Erik Pålsson, Caroline Wass, et al.. (2005). Antagonism of the nitric oxide synthase inhibitor, L-NAME, of the effects of phencyclidine on latent inhibition in taste aversion conditioning. Behavioural Brain Research. 161(1). 60–68. 24 indexed citations
16.
Klamer, Daniel, Jörgen A. Engel, & Lennart Svensson. (2004). The neuronal selective nitric oxide synthase inhibitor, Nω-propyl-l-arginine, blocks the effects of phencyclidine on prepulse inhibition and locomotor activity in mice. European Journal of Pharmacology. 503(1-3). 103–107. 49 indexed citations
17.
Klamer, Daniel, Jörgen A. Engel, & Lennart Svensson. (2004). Phencyclidine‐Induced Behaviour in Mice Prevented by Methylene Blue. Basic & Clinical Pharmacology & Toxicology. 94(2). 65–72. 32 indexed citations
18.
Klamer, Daniel, Jianhua Zhang, Jörgen A. Engel, & Lennart Svensson. (2004). Selective interaction of nitric oxide synthase inhibition with phencyclidine: behavioural and NMDA receptor binding studies in the rat. Behavioural Brain Research. 159(1). 95–103. 19 indexed citations
19.
20.
Klamer, Daniel, Jörgen A. Engel, & Lennart Svensson. (2001). The nitric oxide synthase inhibitor, L-NAME, blocks phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology. 156(2-3). 182–186. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T.I.F.H. Cremers Breakdown of academic impact, for papers by Amy Bullock Breakdown of academic impact, for papers by Michael M. Poe Breakdown of academic impact, for papers by Inna Gaisler‐Salomon Breakdown of academic impact, for papers by Michel M. M. Verheij Breakdown of academic impact, for papers by Katherine M. Nautiyal Breakdown of academic impact, for papers by Brice Le François Breakdown of academic impact, for papers by Yoko Hagino Breakdown of academic impact, for papers by Jesse W. Richardson-Jones Breakdown of academic impact, for papers by James R. Shoblock
Rankless by CCL
2026